INHIBITORS OF HEPATITIS C VIRUS
Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
1 . A compound of Formula (IV):
or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein:
J is C 1 -C 4 alkyl or C 3 -C 6 carbocyclyl, wherein the C 1 -C 4 alkyl or C 3 -C 6 carbocyclyl is optionally substituted with 1-4 halogen, —OH, aryl or cyano;
{circle around (T)} is C 3 -C 5 carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons, wherein said C 3 -C 5 carbocyclylene is optionally substituted with C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, halogen, —OH, or cyano, or {circle around (T)} is C 5 -C 8 bicyclic carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons, or C 3 —C 6 carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons, wherein said C 3 —O 6 carbocyclene is optionally substituted with C 1 -C 4 alkyl or C 1 -C 3 haloalkyl;
L is C 3 -C 6 alkylene, C 3 -C 6 alkenylene or —(CH 2 ) 3 -cyclopropylene-, optionally substituted with 1-4 halogen, —OH, or cyano;
Q is C 2 -C 4 alkyl or C 3 -C 6 carbocyclyl optionally substituted with C 1 -C 3 alkyl, halogen, —OH, or cyano;
E is C 1 -C 3 alkyl or C 2 -C 3 alkenyl, optionally substituted with 1-3 halogen;
W is H, —OH, —O(C 1 -C 3 )alkyl, —O(C 1 -C 3 )haloalkyl, halogen or cyano; and
Z 2a is H or C 1 -C 3 alkyl.
2 . The compound of claim 1 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein J is C 1 -C 3 alkyl.
3 . The compound of claim 1 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein J is methyl or ethyl.
4 . The compound of any one of claims 1 to 3 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein {circle around (T)} is C 3 -C 6 carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons, wherein said C 3 -C 6 carbocyclene is optionally substituted with C 1 -C 4 alkyl or C 1 -C 3 haloalkyl.
5 . The compound of any one of claims 1 to 3 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein {circle around (T)} is C 3 -C 6 carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons, wherein the C 3 -C 6 carbocyclene is optionally substituted with methyl, ethyl or trifluoromethyl.
6 . The compound of any one of claims 1 to 3 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein {circle around (T)} is cyclopropylene.
7 . The compound of any one of claims 1 to 3 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein {circle around (T)} is C 6 -C 8 bridged bicyclic carbocyclylene or C 6 -C 8 fused bicyclic carbocyclylene that is attached to L and to the remainder of the compound of Formula IV through two adjacent carbons.
8 . The compound of any one of claims 1 to 7 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein L is C 3 -C 6 alkylene, substituted with 1-4 halogens.
9 . The compound of any one of claims 1 to 7 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein L is C 5 alkylene, substituted with two halogens.
10 . The compound of any one of claims 1 to 7 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein L is C 3 -C 6 alkylene.
11 . The compound of any one of claims 1 to 7 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein L is C 5 alkylene.
12 . The compound of claim 8 or claim 9 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein the halogens are each fluoro.
13 . The compound of any one of claims 1 to 12 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Q is t-butyl or C 5 -C 6 carbocyclyl.
14 . The compound of any one of claims 1 to 12 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Q is t-butyl.
15 . The compound of any one of claims 1 to 14 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein E is C 1 -C 3 alkyl optionally substituted with 1-3 halogen atoms.
16 . The compound of any one of claims 1 to 14 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein E is difluoromethyl.
17 . The compound of any one of claims 1 to 16 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein W is hydrogen, —O(C 1 -C 3 )alkyl, halogen or cyano.
18 . The compound of any one of claims 1 to 16 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein W is methoxy.
19 . The compound of any one of claims 1 to 18 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Z 2a is hydrogen or methyl.
20 . The compound of any one of claims 1 to 18 , or a stereoisomer, or a mixture of stereoisomers, or a pharmaceutically acceptable salt thereof, wherein Z 2a is methyl.